Pfizer won the ‘Prevenar’ patent nullity suit against SK Chemicals
Pfizer won the Prevenar 13 patent suit proposed by SK Chemicals in 2013.
According to industry concerned on the 12th, the Intellectual Property Tribunal took the side of Pfizer Korea on the lawsuit related to the Prevenar 13’s ‘Polyvalence Pneumococcal Polysaccharide-Protein Zygote Substance Pat...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
